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Foodborne diseases (FBDs) are a major concern worldwide since they are associated
with high mortality and morbidity in the human population. Among the causative agents
of FBDs, Taenia solium, Echinococcus granulosus, Toxoplasma gondii, Cryptosporidium
spp., and Trichinella spiralis are listed in the top global risk ranking of foodborne
parasites. One common feature between them is that they affect domestic livestock,
encompassing an enormous risk to global food production and human health from farm
to fork, infecting animals, and people either directly or indirectly. Several approaches have
been employed to control FBDs caused by parasites, including veterinary vaccines for
livestock. Veterinary vaccines against foodborne parasites not only improve the animal
health by controlling animal infections but also contribute to increase public health by
controlling an important source of FBDs. In the present review, we discuss the advances
in the development of veterinary vaccines for domestic livestock as a strategy to control
foodborne parasitic diseases.
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INTRODUCTION
Foodborne Diseases (FBDs) are a major cause of morbidity andmortality worldwide, affecting one-
third of the global human population each year (World Health Organization, 2015a). Foodborne
Diseases are caused by a broad range of chemical contaminants, bacteria, virus, parasites and
biotoxins, and are often referred as neglected diseases. Despite parasites have not received
the same level of attention as other foodborne biological and chemical hazards, they cause a
high burden of disease in humans (World Health Organization, 2014). In fact, both Food and
Agriculture Organization of the United Nations (FAO) and World Health Organization (WHO)
have recently emphasized the global importance of foodborne parasitic diseases (Trevisan et al.,
2019). Attending this issue, the FAO/WHO Foodborne Disease Epidemiology Reference Group
(FERG) developed amulticriteria-based risk ranking of foodborne parasites at a global level (World
Health Organization, 2014). Among the seven most important parasites listed, Taenia solium,
Echinococcus granulosus, Toxoplasma gondii, Cryptosporidium spp., and Trichinella spiralis share
a common feature: farm animals as important reservoirs (Devleesschauwer et al., 2017). This
issue is of great relevance, not only to human health through the spread of FBDs and their
consequences, but also to the production of food from animal origin because of the economic
losses associated with affected livestock (Gajadhar et al., 2006; Newell et al., 2010). In this regard,
the increase in human population and changes in consumer trends (more proteins in diet) will rise
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the consumption of animal products to 376 million tons by
2030 (Dhama et al., 2013). This huge demand on animal
products, coupled with increasing concern about animal welfare,
is prompting changes in farm-management leading to two
different but potentially dangerous practices: (i) intensive animal
management (Heredia and García, 2018) and (ii) preferences
for animals raised outdoors (“organic animal management”)
(Trevisan et al., 2019). While the intensive management and
processing of products, with an increased movement of foods
globally could lead to defective processing practices and, an
augment of the risk of contamination by foodborne pathogens
at any point of the farm to fork chain (Heredia and García,
2018), the “organic animal management” could lead to a greater
possibility of infection with foodborne parasites (Trevisan et al.,
2019). At this point, it is important to note that the pathways
associated with transmission of foodborne pathogens to humans
are complex and difficult to define, since the “direct” route
from animal to man via meat is only one path, and humans
may also infect one another directly, or contaminate meat
during processing, etc. (Fegan and Jenson, 2018) (Figure 1). In
fact, whereas T. solium, T. gondii, and T. spiralis represent a
potential harm to human health mainly due to the consumption
of undercooked meat or raw food derived from infected
animals (Zolfaghari Emameh et al., 2018), E. granulosus and
Cryptosporidium spp. are transmitted by other pathways, such
as waterborne transmission, direct animal contact, and food
contamination (Table 1).
Epidemiological studies have helped to know the distribution
of these foodborne parasites in domestic livestock and
particularly, the role of cattle, sheep, and pigs in food
contamination (Dhama et al., 2013; Torgerson et al., 2015;
Rousseau et al., 2018). In fact, products of animal origin such
as milk and meat from infected animals with these foodborne
parasites are sources of contamination to other animals and
humans (Davies, 2011; Fegan and Jenson, 2018) (Figure 1).
In addition, livestock generate large volumes of feces, which
can contaminate the environment with (oo)cysts or eggs,
contributing to increase the prevalence of infections transmitted
by some of these parasites in domestic animals (Fayer et al.,
2010). In this sense, it is necessary to establish efficient strategies
to control FBDs caused by these parasites in order to reduce the
effects on animal and human health (Robertson et al., 2014).
There are some generic good practices that are relevant for the
control of foodborne parasites, as well as for other foodborne
biological hazards, which have been reviewed by WHO-FERG
(World Health Organization, 2014) which include control
options enlisted as: (i) “primary production and pre-harvest
measures” (on-farm measures, e.g., on-farm sanitation and
hygiene); (ii) “post-harvest measures” (e.g., slaughtered practices
and production procedures); and (iii) “education measures” (e.g.,
consumer education). In addition, specific guidelines to manage
the most important foodborne parasites were also discussed,
and include, between others, the used of chemotherapeutics
and vaccines in livestock, when commercially available (World
Health Organization, 2014).
In this regard, micro-environments on animal farms are
usually ideal for long-term survival of parasite stages, such
as eggs and oocysts, which are excreted by infected hosts
(Gajadhar and Allen, 2004). The protective structure of the
parasite in the exogenous stages (i.e., stages outside the host)
allowsmany parasites to resist extreme temperatures, desiccation,
and irradiation, making chemical methods commonly used for
virus and bacteria control inefficient for preventing the spread
of protozoa and helminths. Thus, the use of veterinary vaccines
emerges as one of the most promising alternatives to control
foodborne parasites in livestock, particularly in cattle, sheep,
and pigs. This strategy not only would reduce transmission to
humans (McManus and Dalton, 2006), but also the economic
losses caused by the prevalence of these infections in livestock. In
this review we will summarize the advances, future perspectives,
and challenges in the development of veterinary vaccines for
domestic livestock as a control strategy against FBDs caused by
T. solium, E. granulosus, T. gondii, Cryptosporidium spp., and
T. spiralis.
VETERINARY VACCINE DEVELOPMENT
AGAINST FBDs CAUSED BY PARASITES
General Considerations
Since its advent in the 1800s, vaccination remains, without
doubt, the most effective medical intervention to prevent both,
animal and human infectious diseases. Vaccination against
zoonotic or foodborne infections is aimed at reducing or
eliminating the risk for the consumer and, in some cases, to
improve the productivity of the individual animal (Meeusen
et al., 2007). It is generally accepted that the administration
of vaccines for foodborne infections is the best-available public
health intervention and, also represents the best cost-benefit
ratio, occupying a preponderant place within the development
millennium goals: to reduce mortality, to improve health;
and to promote socio-economic development (Hewitson and
Maizels, 2014; McAllister, 2014). In addition to the economic
importance of these diseases, the difficulty of controlling them
by chemotherapeutics methods and development of resistance
against them, make the design of foodborne parasitic vaccines
a relevant issue for human and animal health. In this regard,
the development of antibiotic resistance will progressively reduce
antibiotic therapy options available to veterinarians (Clifford
et al., 2018). Therefore, vaccines would lessen the need for
antibiotics to control diseases and offer veterinary practitioners
much needed tools (Potter et al., 2008; Kolotilin et al., 2014).
Moreover, the growing public interest in production of chemical-
free food, which is fostered by consumer concern about drug
residues in meat, eggs or milk supports the importance of the
development of new veterinary vaccines (Murphy, 2012; Joachim,
2016).
As a strategy to control FBDs caused by parasites, veterinary
vaccine development has practical advantages over human
vaccine development, such as the ability to perform experiments
in the natural host, therefore increasing its chances of achieving
success compared to those of designed for humans, and the
possibility to manufacture live-attenuated vaccines due to the
lower safety requirements (Lightowlers et al., 2016; Zhang N.
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FIGURE 1 | Livestock play a major role in the transmission of FBDs caused by parasites. They may be involved in the direct foodborne route of infection from animal
to human via the consumption of raw meat (e.g., T. solium, T. gondii, T. spiralis infective form in meat), but they may also contribute to human infection through many
other indirect and direct routes. Just to name a few, indirect routes include contamination of water or soil (e.g., Cryptosporidium spp. oocysts shed by cattle),
contamination of fresh produce with eggs/oocysts (e.g., Cryptosporidium spp. oocysts shed by cattle), vertical transmission from mother to fetus after consumption of
infected meat (e.g., T. gondii), infection of definitive hosts (companion animals such as cats and dogs) through the consumption of infected meat from livestock (e.g.,
E. granulosus infected sheep meat consumed by farm dogs) and among other direct routes, the human/animal contact represents an important one (e.g.,
Cryptosporidium spp and T. spirallis in farms and slaughterhouses sources). In the scheme, the arrowhead indicates the sense of the infection route.
TABLE 1 | Main global ranked foodborne parasites that have livestock as an important reservoir and can be transmitted directly or indirectly to humans.
Foodborne
parasites
Human diseases Main domestic and farm
animal hostsς




















Cryptosporidiosis. Cattle Fresh produce and water Ranked 5th 2,159,331
(1,392,438–3,686,925)
T. spiralis Trichinellosis. Pigs Pork Ranked 7th 550 (285–934)
ςTaken from http://www.fao.org/3/a-i3649e.pdf.
§Taken from Devleesschauwer et al. (2017).
*Calculation of Disability Adjusted Life Years taken from Torgerson et al. (2015).
+Toxoplasmosis acquired.
#Congenital Toxoplasmosis.
et al., 2018; Larrieu et al., 2019a). In fact, numerous vaccines
against viral and bacterial infectious diseases have been produced
by animal health companies and have been used for many
decades as prophylaxis against pathogens in veterinary medicine
(Lubroth et al., 2007; Jorge and Dellagostin, 2017). However,
studies concerning vaccine design against foodborne parasites
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using livestock as animal models are scarce (Table 2). In fact, only
few veterinary vaccines against these parasites are commercially
available to be used in livestock, whereas there is none licensed
for humans.
A possible explanation for the scarce progress on vaccine
development against foodborne parasites, could be due to
scientific obstacles, such as the complexity and diversity
of foodborne parasites and a poor understanding of the
host/pathogen interactions (Hewitson and Maizels, 2014; Stutzer
et al., 2018; Sander et al., 2019). These obstacles severely
limit the objective selection of the elements to be considered
in vaccine development, including the choice of the target
species, the vaccine approach, the selection of antigen/s, the
immune response to be targeted, the addition of adjuvants and
the route of vaccination (Chambers et al., 2016). In addition,
the implementation of vaccines against foodborne parasites in
livestock is too expensive compared to chemical control, which is
cheaper and easier to apply by farmers (Lightowlers et al., 2016).
In fact, cost of development, practicality of use, challenges to
licensing, and eventual market value are also crucial elements in
the development of a commercial veterinary vaccine for livestock
(Chambers et al., 2016). Despite these issues, the development of
vaccines against foodborne parasites is still a significant research
topic in medical and veterinary sciences.
Most of the veterinary vaccines evaluated in livestock
against foodborne parasites belong to one of the following
categories: live attenuated vaccines, killed vaccines, or subunit
(and recombinant) vaccines (Table 2). Live-attenuated vaccines
induce a strong humoral and cellular immune response, but
their safety is questionable due to the risk of virulence reversion
(Innes et al., 2011); while inactivated vaccines are safer and
more stable than attenuated ones, but they are less potent and
confer a weaker humoral immunity (Lee et al., 2012). On the
other hand, recombinant subunit vaccines are easy to store,
free of contaminants and proteolytic enzymes since they are
chemically produced, and they are able to induce a protective
immunity without toxic side effects or cross-linked immune
reactions caused by other components present in the pathogenic
organism (Nascimento and Leite, 2012). In addition, large-
scale production and purification of a well-defined product can
be achieved (Purcell et al., 2007). However, there are several
limitations for vaccines based on the use of recombinant proteins,
such as the proper choice of antigen/s, deficient immunogenicity,
and poor cellular immune response (Gander, 2005; Blake et al.,
2017; Sander et al., 2019). In addition, subunit vaccines do not
have enough capacity to activate the innate immune response;
therefore, they require the incorporation of some adjuvant into
the vaccine formulation (Mohan et al., 2013; Sander et al., 2019).
In the following sections we will summarize and analyze the
current veterinary vaccines against the previously mentioned
foodborne parasites that have been evaluated in domestic
livestock, as an attempt to find common features that should
guide the selection of the elements to be included in future
vaccine developments against these challenging pathogens.
Taenia solium
The cestode Taenia solium is at the top of the global multicriteria-
based ranking of foodborne parasites described by FAO/WHO
(Devleesschauwer et al., 2017) (Table 1), and is the causative
agent of cysticercosis in humans and pigs, leading to considerable
health and economic burden (Dixon et al., 2020). In fact, T.
solium neurocysticercosis is the most important preventable
cause of acquired epilepsy, being responsible for more than 30%
of the cases in endemic countries (World Health Organization,
2015b) and probably, in the world (Rajshekhar et al., 2006).
In 2015, the FAO/WHO estimated that more than 50 million
people is infected with this parasite worldwide, resulting in a
considerable total of 2.8 million disability-adjusted life-years
(DALYs) (World Health Organization, 2014). Humans are the
only definitive host of T. solium and acquire taeniasis (the adult
tapeworm infection) eating raw or undercooked pork containing
cysticerci (the larval form of T. solium). In turn, they will shed
eggs of T. solium in their stool, which if ingested by other (or
the same) humans or pigs (the usual intermediate host) will lead
to the development of cysticerci (Sánchez-Torres et al., 2019).
Deficient levels of sanitation as well as pig husbandry practices
and eating habits conditionate the prevalence of T. solium
infection in a determinate region (World Health Organization,
2014).
Despite considerable efforts have been made to establish the
optimal intervention for control and elimination of T. solium,
a recent analysis by de Coster et al. (2018) has concluded that
evidence on this issue is still limited. Several control strategies for
T. solium have been evaluated so far, including vaccination of pigs
and improvement in pig rearing and meat inspection practices
(Okello and Thomas, 2017). However, currently cysticercosis
control is mainly based on treatment of human and pig
with anthelmintic drugs and health control measures through
public education. Treatment of taeniasis in humans as a
strategy to control the parasite burden is known as preventive
chemotherapy, and is implemented as mass drug administration,
targeted chemotherapy or selective chemotherapy; in mass
drug administration the whole population of a predefined
geographical area is treated at regular intervals, irrespective of
clinical status; whereas targeted chemotherapy treats only specific
risk groups at regular intervals and selective chemotherapy
screens patients and subsequently treats according to clinical
status (Okello and Thomas, 2017). Although these interventions
have contributed to reduce the transmission of T. solium,
cysticercosis has not been eradicated from endemic areas or
where housing health conditions are ill-suited. The theoretical
benefits of treating taeniasis on transmission of T. solium
are clear; however, none of the researches carried out until
now have included enough coverage of population or time-
length to achieve a major and sustained reduction in T. solium
transmission (Okello and Thomas, 2017). Hence, the practical
effectiveness of this approach to control T. solium is scarce.
As mentioned above, pigs are the almost exclusive
intermediate hosts of T. solium (Djurković-Djaković et al., 2013).
Therefore, the development of a vaccine for pigs could contribute
to interrupt the parasite’s life cycle and eliminate the main source
of infection for humans (Gonzalez et al., 2005). In fact, it has
been suggested that vaccination of pigs in order to prevent
the development of cysticerci would be considerably more
cost-effective than vaccination of the potentially exposed human
population (Hewitson and Maizels, 2014). Therefore, different
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Vaccine type Antigen +
Adjuvant
Antigen delivery Dose Protection Selected citation
T. solium Pigs Recombinant
protein










Flisser et al., 2004
Gonzalez et al.,
2005
TSOL16 + QuilA i.m. 200 µg Reduction in the
number of cysticerci
(99.8%).
















Flisser et al., 2004
Gonzalez et al.,
2005 (*)
Gauci et al., 2012
TSOL45-1B +
QuilA
i.m. 200 µg No protection Gauci et al., 2012
GK1, KETc1 and
KETc12 + Saponin
























E. granulosus Cattle Recombinant
protein





EG95 + QuilA s.c. 300 µg No protection
EG95 + QuilA s.c. 0–150 µg No protection
EG95 +
Abamectin
s.c. 300 µg No protection
EG95 + ISA 264 s.c. 300 µg No protection
EG95 + ISA 773 s.c. 300 µg No protection
EG95 + QuilA +
ISA264
s.c. 300 µg No protection
EG95 + QuilA +
ISA773
s.c. 300 µg Reduction in the
number of cyst (71%)
EG95 + QuilA +
To16/18
s.c. 250 µg Reduction in number of
cysts (88–99%)
EG95 + QuilA s.c. 250 µg (to
pregnant cows)
Reduction in the




Heath et al., 2012a
EG95 + QuilA s.c. 250 µg (to
pregnant cows) +
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Vaccine type Antigen +
Adjuvant
Antigen delivery Dose Protection Selected citation





















Reduction in number of
cysts (96%)
Reduction in number of
cysts (97%)
Reduction in number of
cysts (96%)






s.c. 50 µg Reduction in number of
cysts (84.2%)
Poggio et al., 2016
EG95 + adjuvant
(N.I.)
s.c. 50 µg Reduction of the
infected 6-years old
lambs from 56.3 to
21.3%.
Reduction in the
















































DNA GRA1 + CpG +
liposomes
GRA4 + CpG +
liposomes
GRA6 + CpG +
liposomes

















ROP1 + CpG i.m. 150 µg, 300 µg,
400 µg, 600 µg,













MIC3 + CpG +
liposomes
i.m. 1mg N.D. Hiszczynska-
Sawicka et al.,
2012






Dubey et al., 1991
(Continued)
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Vaccine type Antigen +
Adjuvant
Antigen delivery Dose Protection Selected citation
RH tachyzoites +
IFA+ CpG
i.m. 4000 tachyzoites Reduction in the
number of infected pigs
(>52%)
Kringel et al., 2004









Reduction in number of
infected pigs (30%)
Reduction in the
number of infected pigs
(20%)
García et al., 2005
Rhoptry protein
extract + QuilA
i.n. 200 µg Reduction in the
number of infected pigs
(41.6%)





s.c. 2mg Reduction in the
number of infected pigs
(80%)




i.m. 500 µg Reduction in the




DNA GRA1 and GRA7
+ pJV2004 and
pJV2005
i.d. 500 µg Reduction in the




C. parvum Cattle Attenuated strain Lyophilized
oocysts












C7 protein (part of














s.c. 300 µg Reduction in oocyst
shedding and delayed
its onset




s.c. N.I. N.D. Burton et al., 2011




i.p. 250–4,000 µg Reduction in the














Marti et al., 1987
The name given to the antigen in the study of Gonzalez et al. (2005) was TSOL45 whereas in the description of the used antigens, the authors cited that of Flisser et al. (2004), which
corresponded to TSOL45-1A.
N.D, not determined; N.I, not informed; i.d, intradermal; i.m, intramuscular; i.n, intanasal; i.p, intraperitoneal; s.c, subcutaneous.
larval antigens from T. solium have been studied as potential
vaccine candidates (Kaur et al., 2020). In this sense, Flisser et al.
(2004) designed a highly efficient recombinant vaccine based
on an 18-kDa protein from T. solium oncospheres (TSOL18).
Intramuscular vaccination of pigs with 200 µg of TSOL18
recombinant antigen + QuilA induces a high level of protection
after the challenge with the parasite (Flisser et al., 2004; Gonzalez
et al., 2005). Interestingly, independent experimental vaccine
trials were conducted in Mexico, Peru, Cameroon and Honduras
with similar promising results (Lightowlers, 2013). The assays
demonstrated that TSOL18 vaccine is able to induce around
99–100% protection against an experimental challenge infection
with T. solium eggs in pigs (Flisser et al., 2004; Gonzalez
et al., 2005; Lightowlers, 2006). Later, Assana et al. (2010a)
carried out field trials in Cameroon. The authors noted that
the combination of TSOL18 vaccination together with a single
oxfendazole treatment led to the complete elimination of T.
solium transmission to pigs. In addition, they demonstrated that
a TSOL18 vaccination schedule based on administration of the
formulation at intervals of 3–4 months between the first and
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 June 2020 | Volume 10 | Article 288
Sander et al. Veterinary Vaccines Against Foodborne Parasites
second immunization was effective in pigs (Assana et al., 2010b).
In a more recent study, Poudel et al. (2019) demonstrated that
the vaccination of pigs with Cysvax R©, currently the first and
only cysticercosis vaccine licensed for commercial production by
Indian Immunologicals Ltd (World Health Organization, 2020),
based on the TSOL18 antigen, together with medication with
oxfendazole, undertaken at 3-monthly interval over a 10-month
period in a T. solium endemic region of Nepal, eliminated the
transmission of the helminth among the animals. These results
suggest that the use of vaccines and chemotherapies together
increases the chances of reducing the transmission rate of
taeniasis/cysticercosis to humans through the consumption of
pork, since drug treatment eliminated any existing infection in
pigs while the vaccine prevented potential subsequent infection.
However, the high costs of these treatment schemes, in addition
to the fact that human is the definitive host of T. solium, make
their implementation difficult. As an alternative approach,
some authors suggested that the strategic drug-treatment of
T. solium infection in humans, after a combined vaccine +
drug intervention in the pig population may provide a fast and
effective method for T. solium control (Assana et al., 2010b;
Lightowlers, 2013; de Coster et al., 2018; Braae et al., 2019;
Poudel et al., 2019). This strategy was recently supported by
field studies by Okello et al. (2017) in the Southeast Asian area
based on the application of two rounds of community mass
drug administration with three consecutive doses of albendazole
400mg at 6 months interval, combined with pig vaccination
(TSOL18) and treatment (OXF), followed by a repeat pig
treatment 1 month later for three iterations (first two combined
with the human mass drug administration), which resulted
in a significant decrease in human taeniasis and prevalence.
Moreover, García et al. (2016) demonstrated that a similar
strategy, based on human mass drug administration combined
with pig mass drug administration and vaccination implemented
in the entire rural region of Tumbes in Perú, achieved the
interruption of transmission of taeniasis in 105 of 107 villages
through a 1-year attack approach and elimination persisted in
most areas for at least 1 year without further intervention. In
addition, this strategy was also supported by Braae et al. (2019),
based on the predictions of a mathematical/computational
model, “cystiSim”, considering basic aspects of T. solium biology
and a dynamic pig population, but, as other simulation studies,
it has several limitations.
In addition to TSOL18, other recombinant proteins from T.
solium oncospheres have been evaluated as candidate vaccine
antigens in pigs, such as TSOL45-1A, TSOL45-1B (both protein
isoforms of the family of related antigens designated as TSOL45)
and TSOL16. Intramuscular vaccination of pigs with 200
µg of recombinant TSOL16, a protein associated with the
penetration gland cells within T. solium, plus QuilA, conferred
99.8% protection in immunized animals against T. solium eggs
challenge (Gauci et al., 2012), whereas results from TSOL45-1A
were confusing. While the studies conducted by Flisser et al.
(2004) and Gonzalez et al. (2005) showed that vaccination of pigs
with this recombinant antigen conferred >97% protection after
challenge with T. solium eggs, Gauci et al. (2012) demonstrated
that TSOL45-1A did not provide statistically significant levels
of protection against T. solium infection. On the other hand,
intramuscular immunization of pigs with 200 µg of recombinant
TSOL45-1B did not conferred protection against T. solium
infection (Gauci et al., 2012).
In a different approach, three epitopes from T. crassiceps
antigens that cross react with T. solium named GK1, KETc1, and
KETc12 were used in the form of synthetic peptides as a three
peptide-synthetic vaccine (S3P) against porcine cysticercosis.
The subcutaneous immunization (250–500 µg of each peptide
plus saponin) of pigs naturally exposed to the parasite during
12 months with S3P vaccine decreased the total number of
T. solium viable cysts (97.9%) and reduced the prevalence of
porcine cysticercosis (52.6%) in the field trial (Huerta et al.,
2001). In an attempt to improve this vaccine, the three peptides
(KETc1, KETc12, GK1) and a recombinant antigen KETc7 were
expressed in bacteriophages at multiple copies. The pool of the
four recombinant-heat inactivated phages induced high levels
of protection against experimental cysticercosis in immunized
pigs, evaluated as reduction in viable cysticerci (52% of non-
viable cysticerci for subcutaneous immunization vs. 75% for oral
immunization) (Manoutcharian et al., 2004). However, field trials
are still needed to evaluate the effectiveness of the recombinant
phage S3P vaccine (Manoutcharian et al., 2004). In this regard, a
number of studies have also explored the expression of antigens
from T. solium in edible plants (Monreal-Escalante et al., 2016)
and the use of DNA-vaccines as an alternative approach with
promising results, but these vaccines have not been optimally
evaluated in pigs so far (Sciutto et al., 2007).
Echinococcus granulosus
Echinococcus granulosus, is a small cestode from the Taeniidae
family and the causal agent of cystic echinococcosis (CE), also
known as hydatidosis, one of the most important zoonotic
parasitic disease in humans worldwide (Pourseif et al., 2018).
Unlike taeniasis/cysticercosis, which is endemic in rural areas
in developing countries, CE is still prevalent in some regions
of industrialized countries (Gajadhar et al., 2006). According
to a recent WHO report, almost 3 million people are infected
with E. granulosus worldwide, and that human CE prevalence is
as high as 5–10% in endemic regions such as Argentina, Peru,
Central Asia, China and East Africa. It is estimated that CE
causes approximately 1 million DALYs annually, leading to an
increasing public health and socio-economic concern in many
areas of the world (World Health Organization, 2014).
E. granulosus requires two mammalian hosts to complete
its life cycle. The definitive hosts are mainly canids, including
the domestic dogs, which passes the segments of the adult
parasite containing eggs or free eggs into the environment
with its feces. The eggs are ingested by the intermediate host
(many mammalian species, including sheep, goats, cattle and
humans), in which larval stage and infectious elements develop
and cause CE (World Health Organization, 2014). Despite CE is
not considered to be “strictly” a foodborne disease, FAO/WHO
experts suggested that it is mandatory to study its foodborne
route, since it is one of the major contributors to the global
burden of parasitic zoonosis (World Health Organization, 2014).
In addition to its relevance to both, human and animal health,
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CE generates important losses in the livestock industry, affecting
leather quality, milk production, and/or animal fertility. In this
sense, the prevalence in livestock varies from 20 to 95% in
slaughterhouses (World Health Organization, 2011).
Conventionally, the human treatment of CE relies on surgery
and/or chemotherapy, which is based on 2 benzimidazole
carbamates, mebendazole, and albendazole, which are the
only anti-infective available drugs clinically efficient to avoid
the larval growth of Echinococcus spp. (Wen et al., 2019).
However, these drugs can cause severe side-effects, particularly
in immunocompromised patients (Wen et al., 2019). Moreover,
the mortality rate, among surgical cases, is about 2 to 4%, and
increases if surgical and medical care are inadequate (World
Health Organization, 2014). In order to control the life cycle
of the parasite from dogs to humans or livestock, different
strategies have been conducted, mostly by the use of anthelmintic
drugs, promotion of slaughter hygiene and education (Craig
et al., 2017; Larrieu et al., 2019a). A few CE control programs,
based mainly in the administration of this drug to dogs, have
been successful in insular countries such as New Zealand and
Tasmania, but in continental endemic countries only moderate
effectiveness in CE control have been made, probably because
of the requirement to administer praziquantel to dogs in rural
areas eight times per year over numerous years (Larrieu et al.,
2019a). In this regard, Pourseif et al. (2018) suggested that,
in comparison with chemotherapies, prophylactic vaccines may
provide much more effective therapies against CE. Despite the
vaccination of dogs (the main host for the prevalence of CE) may
provide better clinical outcomes and may be much economical
than vaccination of the intermediate hosts (sheep and humans),
the population of homeless stray dogs in rural areas of endemic
countries is not controlled; which results in a lesser interest for
this particular vaccine development (Pourseif et al., 2018). The
recent advent of a vaccine against E. granulosus targeted to sheep
has demonstrated that vaccination of intermediate hosts of E.
granulosus could reduce the level of parasite transmission and
decrease the incidence of human infections (Larrieu et al., 2019a).
Since sheep are the most important intermediate host for CE
and the main source of meat in many countries in the world,
some studies suggest that the combined strategy based on the
vaccination of intermediate hosts (sheep) together with treatment
of dogs with praziquantel would help decrease transmission of
the disease to humans (Torgerson and Heath, 2003; Torgerson,
2006; Larrieu et al., 2019a).
Lightowlers et al. (1996) designed a recombinant vaccine
based on a 45W antigen from the oncosphere of E. granulosus
called EG95 and showed that this vaccine induces a high
protection (around 96–98%) in sheep. Later, several studies were
performed in experimental conditions to evaluate the potential
of EG95 recombinant vaccine on the reduction of parasite
transmission in sheep testing different concentrations of the
antigen with different types of adjuvants (Poggio et al., 2016;
Larrieu et al., 2019b). In addition, Larrieu and colleges have
also assessed the impact of EG95 vaccine under field conditions
(Larrieu et al., 2013, 2015, 2019b). Most of these studies were
carried out in countries where the cystic echinococcosis is
endemic, such as Argentina and Australia (Craig et al., 2017).
Recently, Larrieu et al. (2019a) published a bibliographic review
summarizing the successful cases of EG95 vaccine in sheep.
This vaccine has shown to be highly effective even under field
conditions. The results obtained are very promising, showing
protection levels between 85 and 95%. Currently, EG95 vaccine
has been registered for use in China and pilot programs have
recently been conducted in Argentina, Chile, and Australia
(Larrieu et al., 2019a). Given the effectiveness of EG95 vaccine
in sheep and considering that CE has a high incidence in
cattle, the EG95 vaccine was also assayed in cattle (Wen et al.,
2019). Several studies have shown that immunization with EG95
vaccine induce a remarkable protective efficacy in bovine hosts
against cystic echinococcosis (Heath et al., 2012a,b). In particular,
high level of protection was afforded to calves from cows
subcutaneously vaccinated with 250 µg of EG95 + QuilA after
challenged them 9 or 17 weeks of age (Heath et al., 2012a). This
recombinant vaccine has shown to be successful in cattle under
experimental conditions; however, its effectiveness to be assessed
under field conditions.
Despite EG95 vaccine has demonstrated to avoid infection in
sheep after three doses during the first year of life suggesting that
it would be a practical vaccine for implementation by livestock
farmers; it is necessary to analyze different vaccination schedules
and determine the effect on the reduction of infection in dogs
and humans. In addition, the EG95 vaccine is very expensive,
which limits its application to animals reared only in some of
the most developed countries (Valizadeh et al., 2017). As an
alternative vaccination strategy, a number of important antigen
vaccine candidates targeted against the definitive hosts have been
evaluated in dogs, including a 66-kDa fibrous protein called
EgA31, which plays a key role in infection of humans and
dogs (Petavy et al., 2008); a fatty acid-binding protein from
E. granulosus called E. granulosus differential factor 1 (EgDf1),
involved in the uptake, storage and transport of fatty acids in the
parasite (Chabalgoity et al., 2000); and three proteins from the
family of E. granulosus EgM, called EgM123, EgM4, and EgM9,
potentially involved in egg maturation (Zhang et al., 2006; Zhang
Z. Z. et al., 2018). Despite some promising results have been
obtained in those preliminary studies, these results have not been
confirmed yet.
Toxoplasma gondii
The protozoan Toxoplasma gondii is one of the most successful
parasites worldwide, capable of infecting all warm-blooded
animals, including humans (Innes et al., 2011). Despite ∼25–
30 % of the world’s human population is infected by T.
gondii (Montoya and Remington, 2008), in the majority of
immunocompetent individuals, toxoplasmosis is asymptomatic
(Feustel et al., 2012). However, infection with T. gondii can
cause serious disease in the developing fetus if pregnant women
become infected for the first-time during gestation (Innes and
Vermeulen, 2006). In addition, toxoplasmosis is also known
for its severe sequelae in immunocompromised patients (Luft
and Remington, 1992). In 2015, the FAO/WHO estimated that
more than 20 million people illnesses are caused by acquired
toxoplasmosis, whereas CT affects 500.000 humans worldwide,
resulting in a total of 1.6 million DALYs (Torgerson et al., 2015).
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It was recently estimated that the total economic impact of
foodborne toxoplasmosis is US $ 3,456 million, whose dominant
component is directly related to healthcare costs (Scharff, 2012;
Devleesschauwer et al., 2017). T. gondii is also considered a
parasite of veterinary relevance, since CT and reproductive
failures such as fetal death and abortions also occur in many
other animal species, including livestock such as pigs, sheep and
goats, in which it has been recognized as being responsible for
major economic losses through abortions, stillbirths and neonatal
mortality (Raeghi et al., 2011).
Regarding T. gondii life cycle, it can be divided into sexual
replication, which occurs only in felids, including the domestic
cat (definitive hosts), and the asexual replication, which takes
place in all mammals and birds (intermediate hosts). Horizontal
transmissions to humans are more frequently caused either by
the ingestion of tissue cysts in infected meat or by the ingestion of
soil, water, or food contaminated with sporulated oocysts derived
from the environment, rather than by the direct infection from
feline feces (Robert-Gangneux and Dardéc, 2012). In this regard,
the ingestion of oocysts excreted by cats does not appear to pose
a significant risk of infection in humans, given that oocysts are
not infective when passed from cats to humans, and the duration
of oocyst shedding is short (Kijlstra and Jongert, 2008; Petersen
et al., 2010).
Despite many factors can affect seroprevalence in humans,
infection rates in meat-producing animals play a major role,
considering the relevance of the foodborne route involving the
consumption of raw or undercooked meat. In this regard, sheep
and goats are the main sources of infections to humans, and
also represent the main hosts for this parasite in some countries
(World Health Organization, 2014). The highest prevalence
values have been observed in Europe (65 to 89% in adult sheep),
while in the rest of the continents the prevalence in sheep
is around 30% (Stelzer et al., 2019). On the other hand, the
prevalence of toxoplasmosis in pigs is also high in some endemic
areas (Djurković-Djaković et al., 2013). The presence of T. gondii
in pigs is not only a source of infection for humans, but also
an important cause of mortality in pigs, especially in neonatal
ones (Dubey, 2009; Stelzer et al., 2019). Although raising pigs
indoors in confinement has greatly reduced T. gondii infection
in pigs, the recent trend of organic farming is likely to increase T.
gondii infection in pigs again (Guo et al., 2015). In fact, recent
estimations showed that pork consumption is responsible for
around 12–15% of T. gondii infections in humans (Kijlstra and
Jongert, 2008).
Toxoplasma gondii is a challenging parasite to control because
of the large number of possible vehicles, both for foodborne
and non-foodborne infections (World Health Organization,
2014). Control strategies against T. gondii based on education
of high-risk consumers, particularly pregnant women, and
immunocompromised individuals, are imperative (Innes and
Vermeulen, 2006; Devleesschauwer et al., 2017). Despite the
health concern in the human population and the economic
losses in livestock associated with T. gondii infection, there is
neither animal nor human treatment able to eliminate it from
the host once the chronic infection has been established (Innes,
2010). Currently, the human chemotherapies againstT. gondii are
based in the administration of sulfadiazine and pyrimethamine
(Daraprim) (Alday and Doggett, 2017). However, their side effect
makes these treatments inefficient. Additionally, spiramycine
is used in CT to treat infection during pregnancy, but its
administration is still controversial, since multicenter studies
conducted in Europe have shown conflicting results about its
efficacy (Sander et al., 2018). Although prevention of the severe
consequences of CT in pregnant women would be a major target
for a human vaccine, there has been scarce progress on this
issue, a possible reason may be the fact that CT is generally not
considered a priority for public health (Innes et al., 2019). There
are also scientific obstacles, including that the best protective
results of vaccines against T. gondii have been observed with
live vaccine preparations, but there are safety and regulatory
issues that may impede their use in humans (Innes et al., 2011).
Killed or subunit vaccines represent a more safer approach, but
there challenges to overcome, including that they are generally
associated with a poor cellular immune response, one of the
most important features to get a proper protection against T.
gondii infections (Sander et al., 2018, 2019). Recent advances in
understanding the key protective immune responses may help to
determine predictive algorithms for protective epitopes in order
to design better subunit vaccines (Innes et al., 2019). In addition,
as CT is similar in women and sheep, an animal model based in
sheep may be helpful in progressing a vaccine against human CT
(Innes and Vermeulen, 2006).
Regarding the control measures against T. gondii infection
in livestock, as in the case of other foodborne parasites, it has
been suggested that the combination of different approaches
is the optimal strategy, including the implement of farm
biosecurity protocols, hygienic measures and management
practices. However, these control measures alone are not
economically viable or completely effective, thus, it is necessary
to additionally apply immune chemotherapeutic tools (Zhang N.
et al., 2013). However, no safe and effective drug is currently
available for toxoplasmosis in livestock. In fact, even if a drug
were developed to eradicate the chronic infection in food-
producing animals, its administration would represent a risk
related to an increase in drug resistance and to drug residues
entering in the food chain (Hiszczynska-Sawicka et al., 2014;
Sánchez-Sánchez et al., 2018). Therefore, the development of a
prophylactic treatment based on vaccination seems to be the
most effective method to avoid the spread of the disease in
livestock. Moreover, a vaccine against toxoplasmosis in farm
animals would also help prevent infection to humans through
safe meats reducing costs due to the rigorous following up
of at-risk pregnant women, and control parasite reactivation
in immunocompromised patients in order to avoid the use
of toxic drugs during toxoplasmosis treatment (Mui et al.,
2008). However, only one commercial vaccine is commercially
available in UK, France, and New Zealand against T. gondii,
and its use is limited to sheep (Sander et al., 2018). This live-
attenuated vaccine (Toxovax R©) was obtained from a modified
strain (S48) of T. gondii originally isolated from an aborted lamb
in New Zealand. By repeated passage in mice for many years,
the strain lost the capacity to form tissue cysts and oocysts.
Buxton et al. (1991) demonstrated that the vaccination of ewes
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before mating with S48 tachyzoites increases the number of
viable lambs after experimental challenge with T. gondii oocysts
during pregnancy. Additionally, it was demonstrated that one
subcutaneous injection of this 2ml suspension induces protective
immunity for at least 18 months (Buxton, 1993). Despite the
effectiveness of this vaccine, there are some controversial points
that would explain why it has not been implemented in other
countries (Sander et al., 2018). Toxovax R© is a live-attenuated
vaccine, which carries the risk of reverting to a pathogenic strain
and causing disease, in humans and other hosts. In addition,
Toxovax R©, was unsuccessful in preventing toxoplasmosis in pigs,
therefore different approaches in the development of vaccines
against T. gondii have been conducted to reduce the incidence
of toxoplasmosis in this species. Firstly, Dubey et al. (1991)
demonstrated that immunization of pigs with 1× 106 tachyzoites
of live T. gondii RH tachyzoites reduced parasite load in animal
tissues. Later, Kringel et al. (2004) assessed whether the addition
of a CpG motif to 4000 RH tachyzoites enhanced protection
levels. The results showed that ∼52% of the examined tissue
from vaccinated pigs was free of T. gondii (Kringel et al.,
2004). In addition, immunizations were also performed using
different fractions of T. gondii protein extracts. García et al.
(2005) evaluated subcutaneous vaccination of pigs with 100 µg
of T. gondii crude rhoptry proteins in ISCOMs. Although the
immunization was able to induce a humoral response against
the parasite, only 20% of vaccinated animals were free of
tissue cysts (García et al., 2005). Later, da Cunha et al. (2012)
analyzed intranasal immunizations with 200 µg of T. gondii
rhoptry proteins plus QuilA. The authors observed a 41.6% of
protection against challenge infection in pigs. More recently,
Wang et al. (2013) revealed that the subcutaneous immunization
with 2mg of tachyzoite-pooled excreted–secreted antigens (ESA)
supplemented with Freund’s adjuvant was capable of reducing the
levels of cysts in themuscle. Tissue cysts were not detected in 80%
of immunized pigs (Wang et al., 2013). In a more recent study,
Rahman et al. (2019) evaluated the efficacy of intramuscular
immunization of pigs with 500 µg of total lysate antigens (TLA)
from T. gondii. The TLA + QuilA vaccine induced a strong
immune response and reduced the parasite DNA load below
the detection limit in most pigs. Finally, recombinant antigens
have been evaluated by DNA vaccines. Jongert et al. (2008)
evaluated whether intradermal DNA vaccination with GRA1 and
GRA7 proteins from dense granules was able to generate immune
responses and to protect against tissue cyst formation in pigs. The
authors demonstrated that administration of 500 µg of a cocktail
DNA vaccine + pJV2004 and pJV2005 as adjuvants is able to
elicit humoral and cellular immune responses against T. gondii
in pigs and the protection achieved was around 70%. Similarly,
efforts are being made to find a safer vaccine formulation for
sheep, and this is clearly due to the significant economic and
welfare impacts that CT has on the sheep livestock worldwide
(Innes et al., 2019). In addition, this species may also be a
more relevant animal model than the mouse to test potential
human vaccines against CT, as the disease in pregnant sheep
and pregnant women has similarities, as previously mentioned
(Innes and Vermeulen, 2006). Most research in sheep have
focused on the use of recombinant DNA-based vaccines (Li et al.,
2010; Hiszczynska-Sawicka et al., 2011a,b, 2012). The evaluated
antigens belong to the protein families of dense granules (GRA1,
GRA4, GRA6, and GRA7; Hiszczynska-Sawicka et al., 2011a),
ropthries (ROP1; Li et al., 2010; Hiszczynska-Sawicka et al.,
2011b) and micronemes (MIC3; Hiszczynska-Sawicka et al.,
2012). As with other foodborne pathogens, there are few studies
that have shown conclusive results in livestock. Although all these
studies have demonstrated that the evaluated antigens are capable
of inducing a specific immune response in vaccinated sheep, the
protective capacity of these recombinant vaccines remains to be
elucidated. More promising results were obtained by Mévélec
et al. (2010). They demonstrated that aMic1-3 knockoutT. gondii
strain is able to prevent the abortion in sheep. A dose of 105
Mic1-3 knockout tachyzoites was sufficient to induce protection
after both subcutaneous and intraperitoneal injections. This
experimental trial showed that Mic1-3KO vaccine increase the
rate of viable lambs (62–91%) from vaccinated Bizet ewes
(Mévélec et al., 2010). Despite the promising results, no new
studies were reported to validate the effectiveness of mutant
non-cyst-forming-based vaccine formulations in sheep.
The other area for a vaccination approach is the strategic
vaccination of cats in order to reduce environmental
contamination through a decrease of oocyst-shedding (Innes
et al., 2019). However, a recent modeling study by Bonačić
Marinović et al. (2019) showed that prospects on preventing
oocyst-originated human toxoplasmosis by vaccination in large
populations of cats are not favorable due to the large vaccination
coverage needed, and that this vaccine approach might only
be effective if applied in small cat populations such as those
present in farms. Despite these discouraging conclusions, a few
researches in vaccine development against T. gondii infection
targeted to cats have been done, including the subcutaneous
immunization with live Co-irradiated tachyzoites of T. gondii
Beverley strain (Omata et al., 1996), oral immunization with
ME49 strain tissue cysts (Freyre et al., 2007) or with T. gondii
T-263 strain cysts (Frenkel et al., 1991) or bradyzoites (Freyre
et al., 1993; Mateus-Pinilla et al., 1999). Additionally, subunit
vaccines including as antigens ROP2 (Mishima et al., 2002;
Zulpo et al., 2017) or crude rhoptry proteins (García et al.,
2007; Zulpo et al., 2012) were also tested. However, with the
exception of T-263 strain vaccine, none of the previously
mentioned formulations completely prevented oocyst-shedding
in the tested animals. T-263 strain vaccine showed promising
results, but several issues related to the large-scale production,
distribution and safety of the vaccine resulted in the avoidance
of its commercial production (Choromanski et al., 1995). More
recently, Ramakrishnan et al. (2019) used a CRISPR/Cas9
strategy to engineer a T. gondii strain with defective fertilization
and decreased fecundity that is able to generate oocysts
which fail to produce sporozoites. The immunization of cats
with this engineered parasite strain totally prevented oocyst
excretion following infection with T. gondii. Although these
results are highly encouraging, a vaccine candidate consisting
of a genetically modified live parasite strain will not reach
the commercial markets, at least in the short term, since the
regulatory framework in most countries does not approve the
use of these edited organisms yet.
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Cryptosporidium spp.
Cryptosporidium spp. are ubiquitous protozoan parasites, and
are the causative agents of cryptosporidiosis, a gastrointestinal
disease in a wide variety of vertebrate hosts, including humans
and livestock (Hatam-Nahavandi et al., 2019). Cryptosporidiosis
usually induces self-limiting diarrhea in immunocompetent
individuals, but the infection can be severe and life-threatening,
particularly in immunocompromised individuals and in infants
(Khalil et al., 2018). In fact, in the 1980s, cryptosporidiosis
was recognized as the major cause of chronic diarrhea in
immunosuppressed patients (Current et al., 1983) and later,
it was associated with childhood malnutrition and premature
death in developing countries (Sallon et al., 1988). It was
estimated by FAO/WHO that more than 64 million people are
affected by cryptosporidiosis worldwide, accounting for more
than 2.1 million DALYs (Torgerson et al., 2015). Particularly,
Cryptosporidium is a leading cause of diarrhea morbidity and
mortality in children younger than 5 years (Khalil et al.,
2018). In this sense, a recent study by the Global Burden
of Disease 2016 Stroke Collaborators (2019) estimated that
in children under 5 years, cryptosporidiosis causes 4,224,000
DALYs, but increases to 12,868,500 DALYs after accounting for
undernutrition associated DALYs.
Cryptosporidium spp. are monoxenous (complete life cycle
in a single host) coccidian parasites, which lack of species-
specificity, allowing cross-transmissibility between multiple
hosts. The infectious stages of these parasites, the oocysts,
are shed with the feces of their hosts in their fully infective
form, with no external maturation required (Meinhardt et al.,
1996). Cryptosporidium oocysts may survive and persist in the
environment for long periods (Checkley et al., 2015). Routes
of transmission include waterborne, person-to-person, zoonotic
and foodborne (Devleesschauwer et al., 2017). Currently,
Cryptosporidium spp. are considered the most important cause
of waterborne diarrhea outbreaks worldwide (Checkley et al.,
2015). Despite foodborne transmission of cryptosporidiosis
is thought to be much less common than waterborne or
person-to-person transmission, it is emerging as an important
public health issue (Devleesschauwer et al., 2017). Over 20
Cryptosporidium species and genotypes have been identified
in human patients; however, C. hominis and C. parvum are
responsible for the majority of cryptosporidiosis reported in
people worldwide (Ryan et al., 2016). In addition to the relevance
of cryptosporidiosis as a human health concern, it is also one
of the most important diseases in young ruminants, especially
neonatal calves (Hatam-Nahavandi et al., 2019). The clinical
presentation of C. parvum cause acute gastroenteritis disease
in calves resulting in significant economic and production
losses (Thomson et al., 2017). At this point, it is important
to note that human and farm animal infections occur from
consumption of food and water contaminated with oocysts
presented in the feces of animals and humans. In addition, several
reports suggest a zoonotic transmission of Cryptosporidium spp.
from animals to humans due to simultaneous detection of
Cryptosporidium in livestock and farmers and slaughterhouse
workers (Xiao and Feng, 2008; Jafari et al., 2012; Firoozi et al.,
2019). Therefore, livestock can play a major role as a source of
human cryptosporidiosis since cross-contamination of raw meat
with feces of animal in the slaughterhouses is a risk factor for
human cryptosporidiosis (Xiao and Feng, 2008). Ramirez et al.
(2004) reported a prevalence of Cryptosporidium spp. infection in
US dairy farms as high as 95%, whereas in Europe, prevalence of
20–40% has been reported in young calves. It has been estimated
that the worldwide annual excretion of Cryptosporidium spp.
oocysts by livestock is as high as 3.2 × 1023, with cattle being
the host species causing most environmental contamination,
capable of carrying different Cryptosporidium species, including
C. hominis which implies an associated significant public health
risk (Hatam-Nahavandi et al., 2019).
Several measures have been proposed to control foodborne
cryptosporidiosis, mostly directed to improve water quality
throughout the water supply and food chain (Devleesschauwer
et al., 2017). There are only few options to treat human
cryptosporidiosis, since no vaccine is available and the
only FDA-approved drug, nitazoxanide, does not provide
benefit for malnourished children and immunocompromised
patients with cryptosporidiosis (Ryan et al., 2016). Regarding
chemotherapeutic treatments for livestock, the only licensed
drug against cryptosporidiosis in calves is halofuginone lactate.
Although halofuginone lactate can reduce oocyst shedding and
the duration of diarrhea in calves, it is not capable of completely
preventing or curing the disease (Lefay et al., 2001; Jarvie et al.,
2005). In this scenario, the development of a veterinary vaccine
for cattle against Cryptosporidium spp. has aroused great interest,
since it not only would help prevent disease in calves and reduce
oocyst shedding to the environment, but also would help decrease
zoonotic transmission of cryptosporidiosis from cattle to humans
(Innes et al., 2020). Different approaches have been tested in
cattle to assess the potential of developing a vaccine against
C. parvum (Thomson et al., 2017). Initially, immunization
of newborn calves with killed (γ-irradiated or lyophilized)
C. parvum oocysts (1 × 106-5 × 106 ocysts/ml) resulted in
reduced oocyst shedding and diarrhea when compared to
non-immunized calves (Harp and Goff, 1995; Jenkins et al.,
2004). However, the vaccine did not prove to be efficacious
when tested under field conditions (Harp and Goff, 1995).
Considering that cryptosporidiosis mainly occurs in very young
calves, it is important to take under consideration that it might
be difficult to generate protective immunity against the parasite
quickly enough through active vaccination (Innes et al., 2020).
In this regard, a promising strategy is to immunize dams a few
weeks prior to parturition to generate hyperimmune colostrum
containing high titers of specific antibodies (Innes et al., 2011).
This approach is not only beneficial to control disease in
livestock but also for public health reducing environmental
contamination with Cryptosporidium oocysts (Jenkins et al.,
2004). Up to now, a few antigens have been explored as vaccine
candidates against bovine cryptosporidiosis in pregnant cow.
Perryman et al. (1999) evaluated the recombinant C. parvum
C7 protein containing the C-terminal of the P23 antigen. Cattle
were subcutaneously immunized three times at 2-week intervals
with 300 µg recombinant C7 + trehalose dimycolate (TDM)
and monophosphoryl lipid A (MPL) as adjuvants. The results
showed that calves receiving the immune colostrum from dam
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immunized with this recombinant protein were protected against
diarrhea and showed a significant reduction in oocyst shedding
compared to control animals (Perryman et al., 1999). More
recently, Askari et al. (2016) also evaluated the recombinant P23
protein as a vaccine for passive immunization of newborn calves.
They demonstrated that administration of enriched colostrum
from immunized dams with 300 µg of the recombinant protein
emulsified with Freund’s adjuvant inhibited over 90% the oocyst
shedding by calves. Similarly, Burton et al. (2011) analyzed
the antibody responses in calves fed with colostrum from
dams vaccinated with a recombinant C. parvum oocyst surface
CP15/60 protein. This study showed that calves had measurable
quantities of the specific antibody in their serum, indicating
that the passive immunity vaccine approach may be suitable to
help prevent cryptosporidiosis in livestock (Burton et al., 2011).
Although these developments showed partial success under
experimental conditions, none of them was effective under field
conditions (Innes et al., 2011; Mead, 2014).
On the other hand, the development of a vaccine against
Cryptosporidium that prevents disease or reduces the severity of
infection in humans is a relevant issue, particularly considering
its consequences in early childhood in developing countries.
However, a vaccine targeted to children in the first years
of life brings several “extra challenges,” since in addition to
the poor understanding of the host/parasite interactions and
the uncertainties about the type of immune response that
induces protective responses (a shared feature among foodborne
parasites), vaccines administered to this group may have lower
efficacy due to a number of reasons, including the young age of
the child, interference bymaternal antibodies, deficient nutrition,
etc. (Mead, 2014). Thus, the successful design of a human vaccine
against cryptosporidiosis still remains, without doubt, a long and
winding road.
Trichinella spiralis
The intracellular parasitic nematode Tichinella spiralis, can infect
a wide number of carnivore and omnivore hosts, and is the major
etiological agent of a zoonosis known as trichinellosis, regarded
as an emerging and re-emerging disease in some parts of the
world, particularly in Eastern Europe and Asia (Cuperlovic et al.,
2005; Devleesschauwer et al., 2017). In humans, symptoms of
trichinellosis range from nausea, diarrhea, and fever to more
severe ones, including myalgia, myocarditis, and sometimes,
death (Robertson et al., 2014). All infected animals, including
humans, serve as both definitive hosts and potential intermediate
hosts (Pozio, 2014). However, the human transmission of this
disease is considered 100% foodborne and occurs mainly by the
consumption of raw or undercooked meat and its derivatives
from pigs contaminated with encysted first-stage larvae (Ortega-
Pierres et al., 2015). Although the improvement in animal
husbandry practices, meat inspection, consumer education,
and medical care have contributed to prevent trichinellosis, it
was recently reported that more than 11 million people are
chronically infected with T. spiralis all over the world (Murrell
and Pozio, 2011). In this regard, it was suggested that the risk
of exposure to Trichinella is negligible for livestock produced
under conditions of controlled management (Noeckler et al.,
2019). However, traditional and domestic practices in pig farming
are common in several regions, such as Eastern Europe and
Argentina (Murrell, 2016), leading to an increasing concern
about the risk of spillover of T. spiralis in these areas. On the
other hand, T. spiralis can also cause huge economic burden to
the livestock industry, mainly due to mandatory meat inspection
in many countries ($ 0.12–$ 3.0/pig) (Pozio, 2015; Zhang N. et
al., 2018).
The human treatment of trichinellosis is based on
anthelmintic drugs and should be initiated within a few
weeks after eating contaminated meat. As with other
helminths, chemotherapeutic treatments are mostly based
in the administration of mebendazole or albendazole. Although
these drugs are described as relatively safe, they can induce
bone marrow suppression. In addition, they cannot be used in
pregnant women due to their teratogenic effects (Shimoni and
Froom, 2015). Despite the control measures against trichinellosis
are mainly based in controlled management of domestic pigs
(Gamble et al., 2019) and “post-harvest measures,” including
testing and processing methods, as well as consumer education
(Noeckler et al., 2019), vaccination of pigs represents an
alternative approach to trichinellosis control, especially for
those pigs feeding under backyard or free-ranging conditions
(Zhang N. et al., 2018). In fact, vaccination is able to give a
lifelong protection, diminishing the use of chemical antiparasitic
drugs (Zhang N. et al., 2018). During the last 30 years, several
attempts have been made to develop an effective vaccine against
trichinellosis. In this regard, early protection assays in pigs
against T. spiralis were based in the administration of partially
purified stichosoma antigens from the muscle larvae (ML)
(Murrell and Despommier, 1984) or inactivated newborn larvae
antigens (NBL) (total extracts) (Marti et al., 1987). Various
concentrations were emulsified in Freund’s complete adjuvant
and injected intraperitoneally into the pigs. The stichosoma
antigens induced only moderate protection (14–55%) mainly
directed against the fecundity of female worms, whereas NBL
inactivated vaccine was highly protective in swine (44–51%)
against T. spiralis challenge (Marti et al., 1987). Despite these
promising results, commercial production of an inactivated T.
spiralis vaccine is economically non-viable. Thus, more recent
studies have been focused on the identification of the best T.
spiralis antigens that elicit an effective and safety enteral and
systemic protection in the host. Several vaccine candidates
based on single, multiple or total antigens from different stages
of T. spiralis, used as crude protein extracts, recombinant
proteins or as DNA vaccines, administered alone, or combined
with adjuvants, as well as delivered by live carriers have been
proposed (revised by Zhang N. et al., 2018). However, most
of them were performed using the murine model, and have
been focused in vaccine formulations capable of reducing the
worm fecundity and / or decrease in muscle larval and adult
burdens. In this regard, Bien et al. (2015) undertook a study to
identify immunoreactive proteins from the ML and adult stages
that are specifically recognized by anti-Trichinella antibodies
and found a total of 18 proteins, 3 of them common for both
adult and ML, including heat shock proteins, enolase and
5’-nucleotidase. Despite these proteins may be potential antigens
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 13 June 2020 | Volume 10 | Article 288
Sander et al. Veterinary Vaccines Against Foodborne Parasites
for early diagnosis and the development of a vaccine against the
parasite, further researches must be conducted. In view of the
previous findings, the design of an effective vaccine against T.
spiralis should include multi-epitopes/antigens from different
life cycle stages and a proper adjuvant and/or delivery system
and must be evaluated by different administration routes in the
target species, the pig. These considerations limit advances in




During the last decade, the spread of FBDs caused by parasites
has led to an increasing concern. Indeed, a recent report of
FERG has confirmed that foodborne parasites cause a high
burden of disease in humans (Torgerson et al., 2015). While
the need to reduce the burden of disease of these particular
parasites is obvious, the best interventions to achieve this goal
are not clearly defined. In fact, each of these parasites, as well
as its associated FBD, has unique challenging characteristics,
which turns the selection of the best control measure a very
difficult task. Despite vaccination of farm animals undoubtedly
improves animal health and reduces economic losses associated
with livestock industries, the relevance of livestock vaccination
as a measure to control foodborne parasitic diseases must be
discussed for each FBD (regardless of whether it is meat-borne
or not), since several factors including biological and technical
criteria, as well as available resources, must be taken into account.
Moreover, this intervention must also be weight depending on
the geographical region it would be applied, considering its
particular social and political conditions (Gabriël et al., 2018).
In the case of T. solium, vaccination of pigs arises as one of
the most promising strategies, and the best suitable option to
control cysticercosis, mainly when combined with mass drug
administration in humans (García et al., 2016; de Coster et al.,
2018; Gabriël et al., 2018). Since transmission of the parasite
is associated with social habits and hygiene, such as lack of
use of sanitary facilities in farms, free-range pig husbandry, not
rigorous meat inspection methods, and a lack of encouragement
around safe consumption, interventions to improve this issues
would be beneficial to control this disease, however; to alter these
habits might take more than one generation (de Coster et al.,
2018); thus these options might be considered as “long-term”
measures. On the contrary, the vaccination of pigs combinedwith
anthelmintic administration in humans has shown good results,
leading even to the elimination of cysticercosis in an endemic
area of Perú within a year (García et al., 2016), suggesting
that it represents a potential successful “short-term” measure
(García et al., 2016; Okello et al., 2017; Braae et al., 2019).
However, vaccination with Cysvax R©, the only commercially
available vaccine based in the recombinant E. coli-expressed
antigen TSOL18, requires two to three immunizations to animals,
and a strict cold chain for the vaccine (de Coster et al., 2018), both
items very difficult to attain in certain poor and remote areas.
Thus, an interesting alternative that deserves to be considered
in the development of new vaccine approaches against T. solium
targeted to pigs is the recombinant expression of the highly
immunogenic TSOL18 antigen (or others) in other platforms
in order to produce mucosal or edible vaccines. In this regard,
plants can be a valuable option to produce therapeutic proteins
for animal health (Clemente, 2014; Sander et al., 2018). In
fact, the expression of subunit vaccines in plants, especially for
veterinary use, offer several major advantages when compared
to conventional recombinant protein expression systems such
as bacteria, yeasts, insect cells or mammals, including low-
cost production by eliminating expensive fermentation and
purification systems, scalability, ability to produce complex
proteins, sterile delivery, cold storage/transportation and safety
(Shahid and Daniell, 2016). Most importantly, they represent a
versatile tool for the production of edible vaccines capable of
eliciting immune responses in both mucosal and systemic tissues
and protecting from pathogen invasion at the mucosal surfaces,
thus contributing to the development of more efficient vaccines
(Yácono et al., 2012; Albarracín et al., 2015; Fragoso et al.,
2017; Rosales-Mendoza et al., 2018). Despite these advantages,
it was not until recently that plant-edible vaccines have reached
the commercial market (Concha et al., 2017). Thus, far, only
few studies have explored this approach to develop a vaccine
against T. solium in plants (Monreal-Escalante et al., 2016).
Another element to be considered in order to improve vaccines
in general, and the current TSOL 18 vaccine (considering the
number of immunizations needed per animal), is the addition of
more effective adjuvants. Despite the incorporation of adjuvants
that significantly reduce antigen dose, enhance a broad range
of immune responses and provide protection against pathogens
or related diseases is a necessary trend for the development
of more effective vaccines, research on new adjuvants is still
a challenge in the development of vaccines against foodborne
parasites. However, many molecules have demonstrated their
ability to enhance and modulate the immune response, which
could be incorporated into foodborne parasitic vaccines (Sander
et al., 2019).
In the case of E. granulosus, whether immunization of
domestic livestock (specially targeted to sheep) is the most
suitable approach or not, is difficult to assess. Despite
anthelmintic drug treatment of dogs (the definitive host) has been
a successful tool to control CE in insular regions, it did not render
similar results in continental rural areas, where homeless stray
dogs are usually present and uncontrolled (Larrieu et al., 2019a).
This limitationmust be taken into account also when considering
the development of a vaccine against E. granulosus for dogs. On
the other side, despite CE is not a strictly foodborne disease since
it is not meat-borne transmitted to humans, vaccination of sheep,
the most important intermediate host, could reduce the level
of parasite transmission and decrease the incidence of human
infections (Larrieu et al., 2019a), especially when combined with
the administration of anthelmintics to dogs (Torgerson and
Heath, 2003; Torgerson, 2006; Larrieu et al., 2019a). Currently,
the licensed vaccines against E. granulosus are based on the
EG95 antigen, which has proven effective both for sheep and
cattle (Heath et al., 2012a,b). An important alternative to explore
is the development of multi-epitope veterinary vaccines, which
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 14 June 2020 | Volume 10 | Article 288
Sander et al. Veterinary Vaccines Against Foodborne Parasites
would include potent antigens from both, the adult and larval
stage of the parasite, and thus, could be applied to intermediate
and definitive hosts. In addition, as previously discussed for T.
solium, the establishment of new platforms for production of
safe and highly immunogenic mucosal vaccines, despite highly
encouraged has been scarcely explored (Chabalgoity et al., 2000;
Petavy et al., 2008). Moreover, the development of new and safe
adjuvants, in addition to the identification of novel protective
vaccine antigens are also of high priority.
A different scenario is associated with FBDs caused by
the parasites T. gondii and Cryptosporidium spp. Regarding T.
gondii, as extensively discussed before, control strategies based
on education of high-risk consumers (pregnant women and
immunocompromised individuals) and vaccination of sheep
(and other meat- producing animals), are generally accepted as
some of the most appropriate interventions to control spread of
toxoplasmosis in humans. In the case of Cryptosporidium spp.,
control measures are mostly directed to improve water quality
throughout the water supply and food chain (Devleesschauwer
et al., 2017). In this sense, the development of a veterinary
vaccine for cattle against Cryptosporidium spp. not only would
reduce oocyst shedding to the environment by calves improving,
indirectly the water supply, but also would help decrease
zoonotic transmission of cryptosporidiosis from cattle to humans
(Innes et al., 2020). Despite their differences, these parasites
shared, at least, two common features: i) there is no effective
available commercial vaccine against neither of them; and
ii) they are coccidian parasites. Successful vaccines against
coccidian parasites are scarce and limited to the veterinary field
and excluding Coxabic R© (a subunit vaccine against chicken
coccidiosis), they are based on live attenuated or whole killed
organisms (McAllister, 2014). Despite the rational design of
vaccines against coccidian parasites (and why not, foodborne
parasites in general) has its own difficulties to overcome and
represents singular challenges, there are some common features
that should be taken into account when analyzing their feasibility.
One of the main obstacles in the development of an effective
vaccine against them is to elucidate the mechanisms used by
coccidian parasites to escape the host’s immune system (Wang
et al., 2019). Therefore, it is imperative to shed light about
the cellular and molecular processes that regulate the life cycle
of these parasites in different intermediate and definitive hosts
in order to identify new protective antigens and establish
the mechanisms to monitor and optimize vaccine success.
In fact, the new genomics, proteomics and transcriptomics
techniques have allowed the identification of a broad spectrum
of potential proteins that could serve as vaccine candidates
for T. gondii (Sidik et al., 2016) and Cryptosporidium spp.
(Di Cristina and Carruthers, 2018). An effective approach to
better understand protein function is based in different gene-
editing techniques to construct mutant strains of coccidian
species (Suarez et al., 2017). Among them, the CRISPR/Cas9
technology has proven to be a powerful system, both for T. gondii
and Cryptosporidium spp, to unveil the molecular and cellular
biology of these parasites (Sidik et al., 2016; Di Cristina and
Carruthers, 2018), which in turn, may lead to great progress in
the field of vaccinology, with an increasing impact on animal
health (Wang et al., 2019). As for other foodborne parasites,
the development of novel adjuvants and better delivery systems
(preferentially, development of mucosal and/or edible vaccines)
will greatly improve vaccine formulations against coccidians.
In this regard, the results obtained by the addition of the
most promising plant-derived adjuvants for the development of
coccidian vaccine formulations have been previously reviewed
(Sander et al., 2019).
To assess the actual relevance of a vaccine against T. spiralis
targeted to pigs as a control option to human trichinellosis
is a very difficult issue. Undoubtedly, the development of this
potential vaccine will help decrease the human burden of this
disease (Zhang N. et al., 2018). However, considering that the
risk of exposure to T. spiralis is negligible for livestock under
conditions of controlled management, and that there are some
specific “post-harvest measures” that should prevent human
infection with this parasite through pork consumption, little
attention has been paid to the development of such vaccine.
The rational design of a veterinary vaccine against T. spiralis
for pigs shares the main features previously discussed and
highlighted for other foodborne parasites, such as search formore
potent antigens, novel and safer adjuvants, appropriate delivery
systems, etc.
It is noteworthy that vaccination is a safe tool that would
also help reduce resistance by the misuse of antibiotics and
other drugs. Therefore, it is important to generate public
education strategies to emphasize the importance of vaccination
and its benefits. Public health agencies are responsible for
properly informing about the importance of developing new
vaccine formulations, including new adjuvants, and educating
the population in order to increase compression and acceptance.
In the last decades, many efforts have been focused on the
development of effective immunoprevention against different
foodborne pathologies. Progress to date on vaccination against
parasites in livestock have provided evidence that may contribute
to the development of more effective vaccines against the most
important foodborne parasitic diseases and strongly impact
on human health. To conclude, whereas the control of FBDs
caused by parasites will be facilitated by the development
and administration of veterinary vaccines for livestock, the
achievement of this goal will require more coordinated and better
dialogues between a broad spectrum of actors and stakeholders,
to design and implement control measures that take into account
scientific, cultural, educational, economic and political factors to
tackle these neglected diseases.
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Bonačić Marinović, A. A., Opsteegh, M., Deng, H., Suijkerbuijk, A. W. M., van
Gils, P. F., and van der Giessen, J. (2019). Prospects of toxoplasmosis control by
cat vaccination. Epidemics 30:100380. doi: 10.1016/j.epidem.2019.100380
Braae, U. C., Lightowlers, M. W., and Donadeu, M. (2019). Can we recommend
practical interventions to prevent neurocysticercosis? Trends Parasitol. 35,
592–595. doi: 10.1016/j.pt.2019.04.012
Burton, A. J., Nydam, D. V., Jones, G., Zambriski, J. A., Linden, T. C., Cox, G., et al.
(2011). Antibody responses following administration of a Cryptosporidium
parvum rCP15/60 vaccine to pregnant cattle. Vet. Parasitol. 175, 178–181.
doi: 10.1016/j.vetpar.2010.09.013
Buxton, D. (1993). Toxoplasmosis: the first commercial vaccine. Parasitol. Today
9, 335–337. doi: 10.1016/0169-4758(93)90236-9
Buxton, D., Thomson, K., Maley, S., Wright, S., and Bos, H. J. (1991).
Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma
gondii and their immunity to challenge when pregnant. Vet. Rec. 129, 89–93.
doi: 10.1136/vr.129.5.89
Chabalgoity, J. A., Moreno, M., Carol, H., Dougan, G., and Hormaeche, C.
E. (2000). Salmonella typhimurium as a basis for a live oral Echinococcus
granulosus vaccine. Vaccine 19, 460–469. doi: 10.1016/S0264-410X(00)00197-3
Chambers, M. A., Graham, S. P., and La Ragione, R. M. (2016). Challenges in
veterinary vaccine development and immunization. Methods Mol. Biol. 1404,
3–35. doi: 10.1007/978-1-4939-3389-1_1
Checkley, W., White, A. C., Jaganath, D., Arrowood, M. J., Chalmers, R. M.,
Chen, X. M., et al. (2015). A review of the global burden, novel diagnostics,
therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect. Dis. 15,
85–94. doi: 10.1016/S1473-3099(14)70772-8
Choromanski, L., Freyre, A., Popiel, R., Brown, K., Grieve, R., and Shibley, G.
(1995). Safety and efficacy of modified live feline Toxoplasma gondii vaccine.
Dev. Biol. Stand. 84, 269–281.
Clemente, M. (2014). “Plant-based vaccines against Toxoplasmosis,” in Genetically
Engineered Plants as a Source of Vaccines Against Widespread Diseases: An
Integrated View, ed S. Rosales-Mendoza (New York, NY: Springer), 1–287.
doi: 10.1007/978-1-4939-0850-9_11
Clifford, K., Desai, D., Prazeres da Costa, C., Meyer, H., Klohe, K., Winkler, A. S.,
et al. (2018). Antimicrobial resistance in livestock and poor quality veterinary
medicines. Bull. World Health Organ. 96, 662–664. doi: 10.2471/BLT.18.209585
Concha, C., Cañas, R., Macuer, J., Torres, M. J., Herrada, A. A., Jamett, F.,
et al. (2017). Disease prevention: an opportunity to expand edible plant-based
vaccines? Vaccines 5:14. doi: 10.3390/vaccines5020014
Craig, P. S., Hegglin, D., Lightowlers, M. W., Torgerson, P. R., and Wang, Q.
(2017). Echinococcosis: control and prevention. Adv. Parasitol. 96, 55–158.
doi: 10.1016/bs.apar.2016.09.002
Cuperlovic, K., Djordjevic, M., and Pavlovic, S. (2005). Re-emergence of
trichinellosis in southeastern Europe due to political and economic changes.
Vet. Parasitol. 132, 159–166. doi: 10.1016/j.vetpar.2005.05.047
Current, W. L., Reese, N. C., Ernst, J. V., Bailey, W. S., Heyman,
M. B., and Weinstein, W. M. (1983). Human cryptosporidiosis in
immunocompetent and immunodeficient persons. Studies of an outbreak
and experimental transmission. N. Engl. J. Med. 308, 1252–1257.
doi: 10.1056/NEJM198305263082102
da Cunha, I. A. L., Zulpo, D. L., Bogado, A. L. G., de Barros, L. D., Taroda, A.,
Igarashi, M., et al. (2012). Humoral and cellular immune responses in pigs
immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus
Quil-A. Vet. Parasitol. 186, 216–221. doi: 10.1016/j.vetpar.2011.11.034
Davies, P. R. (2011). Intensive swine production and pork safety. Foodborne
Pathog. Dis. 8, 189–201. doi: 10.1089/fpd.2010.0717
de Coster, T., Van Damme, I., Baauw, J., and Gabriël, S. (2018). Recent
advancements in the control of Taenia solium: a systematic review. Food
Waterborne Parasitol. 13:e00030. doi: 10.1016/j.fawpar.2018.e00030
Devleesschauwer, B., Bouwknegt, M., Dorny, P., Gabriël, S., Havelaar, A. H.,
Quoilin, S., et al. (2017). Risk ranking of foodborne parasites: state of
the art. Food Waterborne Parasitol. 8–9, 1–13. doi: 10.1016/j.fawpar.2017.
11.001
Dhama, K., Rajagunalan, S., Chakraborty, S., Verma, A. K., Kumar, A., Tiwari,
R., et al. (2013). Food-borne pathogens of animal origin-diagnosis, prevention,
control and their zoonotic significance: a review. Pak. J. Biol. Sci. 16, 1076–1085.
doi: 10.3923/pjbs.2013.1076.1085
Di Cristina, M., and Carruthers, V. B. (2018). New and emerging uses of
CRISPR/Cas9 to genetically manipulate apicomplexan parasites. Parasitology
145, 1119–1126. doi: 10.1017/S003118201800001X
Dixon, M. A., Braae, U. C., Winskill, P., Devleesschauwer, B., Trevisan, C., Van
Damme, I., et al. (2020). Modelling for Taenia solium control strategies beyond.
Bull. World Health Organ. 9, 198–205. doi: 10.2471/BLT.19.238485
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